[go: up one dir, main page]

WO1998039411A1 - Lignees cellulaires de complementation de la region e1 d'un adenovirus - Google Patents

Lignees cellulaires de complementation de la region e1 d'un adenovirus Download PDF

Info

Publication number
WO1998039411A1
WO1998039411A1 PCT/US1998/003473 US9803473W WO9839411A1 WO 1998039411 A1 WO1998039411 A1 WO 1998039411A1 US 9803473 W US9803473 W US 9803473W WO 9839411 A1 WO9839411 A1 WO 9839411A1
Authority
WO
WIPO (PCT)
Prior art keywords
deleted
adenovirus
cell
recombinant
mammalian cell
Prior art date
Application number
PCT/US1998/003473
Other languages
English (en)
Other versions
WO1998039411A9 (fr
Inventor
David Ayares
Ramon Alemany
Wei-Wei Zhang
Original Assignee
Baxter International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc. filed Critical Baxter International Inc.
Priority to EP98908661A priority Critical patent/EP0973866A4/fr
Priority to JP10538574A priority patent/JP2000509614A/ja
Priority to CA002283253A priority patent/CA2283253A1/fr
Publication of WO1998039411A1 publication Critical patent/WO1998039411A1/fr
Publication of WO1998039411A9 publication Critical patent/WO1998039411A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • This invention relates to novel cells and methods for use in propagating El- deleted adeno viruses.
  • adenoviral vectors used in gene therapy applications were designed to have deletions in the El region of the adenovirus 5 (Ad5) genome.
  • the El region, not including region IX, consists of 9% of the left end of Ad5 (1.2 - 9.8 map units), and is subdivided into two regions, E1A and E1B, each one coding for several proteins.
  • E1A/E1B is required for virus replication and for expression of all other Ad5 proteins (E2-E4, Late Proteins; Ginsberg, H.S. The Adeno viruses. Plenum Press, New York. p.46-67(1984).
  • El deficient adenoviral vectors are propagated in an Ad5 helper cell line called 293 (Graham, F.L. and Smiley, J, J. Gen. Virol. 36, p.54-72 (1977).
  • 293 cells were derived by transforming human embryonic kidney cells with sheared fragments of Ad5 DNA. Genomic analysis revealed that 293 cells contain four to five copies per cell of the left 12% of the viral genome (including the entire El region) and approximately one copy per cell of 9% of the right end, the E4 region (Aiello,L.,et al, Virology 94, p.460-469 (1979).
  • RCA in 293 cells can present severe ramifications for the safety of human gene therapy trials (Lochmuller, H., et al., Human Gene Therapy 5 . , p. 1485-1491 (1994).
  • recombination in 293 cells can also cause deletions and rearrangements that affect transgene expression, thereby decreasing the titer of functional adenovirus particles.
  • This invention encompasses a series of helper cell lines for the complementation, amplification, and controlled attenuation of El-deleted adenovirus. These cell lines are advantageous because they can complement adenovirus El gene deletions without production of replication competent adenovirus (RCA).
  • a preferred embodiment is an A549E1 cell line that contains only the Ad5 El DNA sequences sufficient for complementation of El -deleted adenoviral vectors without sequences that overlap with the adenovirus vector.
  • the El DNA sequences comprise El A and E1B genes.
  • the present invention embodies methods for selectively propagating mini-adenovirus without generating RCA, by transfecting an A549E1 cell line with DNA sequences that encode a polypeptide sufficient for packaging attenuation of El -deleted helper virus.
  • the polypeptide comprises Cre recombinase.
  • the polypeptide comprises TetR-KRAB.
  • Figure 1 is a diagram indicating the structure of adenovirus sequences in a typical El- deleted Ad helper virus (top line), in 293 cells (ref.5), and in other El -containing cell lines, including 911 cells (ref.8) and A549E1-68 cells (this invention); and how recombination between homologous adenovirus sequences occurs to generate a replication-competent adenovirus (RCA).
  • Figure 2 is a diagram of the CMV-E1 mammalian expression vector.
  • Figure 3 is a Southern blot analysis of G418 r A549E1 clones.
  • Figure 4A is a Western blot analysis of El A protein expression in A549 cells, 293 Cells, and A549El-68.
  • Figure 4B is the metabolic 35 S labeling and immunoprecipitation of EIB proteins in
  • Figure 5 is a representation of the El -deleted adenovirus vector, Ad5-CA-GFP.
  • Figure 6 is an agarose gel analysis of 40 PCR reactions using ElA-specific primers for detection of RCA.
  • Figure 7 is a diagram of a system for the attenuation of helper virus with a loxP -modified packaging signal.
  • Figure 8 is a diagram of the pCMV-Cre-Puro vector.
  • Figure 9 is a diagram of the pBS/loxP-stop/MCLpA vector.
  • Figure 10 is a bar graph depicting luciferase expression in both control cells (A549E1-
  • This invention provides cell lines that can complement El -deleted adenovirus without the disadvantage of undesirable recombination and RCA. These cell lines are obtained by cloning and expressing in the A549 cell line only those sequences that are required for El complementation and excluding from the cell line all other Ad5 sequences that have homology to the vector and could cause recombination to produce RCA.
  • FIG. 1 shows the structure of adenovirus sequences in 293 cells versus other El -containing cell lines (including A549E1 cells), and how recombination between homologous adenovirus sequences occurs to generate a replication-competent adenovirus (RCA).
  • RCA replication-competent adenovirus
  • A549E1-68 contains no sequence overlap with sequences present in the El -deleted Ad helper virus and thus, recombination to produce RCA is not possible (FIG. 1). Characterization of this A549E1 cell line demonstrated the production of El A and EIB proteins, high infectivity with adenovirus vectors, complementation of El- deleted adenovirus to produce high-titer virus stocks, as well as, the lack of production of replication-competent adenovirus (RCA).
  • A549-E1 complementing cell lines which, in addition to producing El, also produce proteins required for further manipulation of adenoviral vectors, thus providing a novel series of RCA-free adenovirus helper cell lines, as tools for novel virus production.
  • the first example is an A549E1 cell line which expresses the Cre recombinase.
  • This invention provides a novel El -deleted helper virus whose packaging signal is flanked by loxP sites, and when this helper virus is propagated in an A549E1 cell line expressing Cre, the packaging signal is deleted by excision, thus attenuating helper virus packaging and enriching for packaging of mini-adenovirus (Ad5 virus which is devoid of all viral protein-coding sequences).
  • This is advantageous because during the production of helper-dependent, mini-adenovirus it becomes necessary to attenuate helper virus packaging in order to enrich for the mini-virus.
  • 293-Cre cells have been generated for this purpose (Parks, R. , et al, P.N.A.S. 93, p.13565-13570 (1996), however, A549E1- Cre cells have an advantage in that they would perform this task in an RCA-free environment.
  • a further embodiment of the present invention includes an A549-E1 complementing cell line which expresses the TetR-KRAB fusion protein, which would be used to amplify, and control the packaging efficiency of an El -deleted helper virus whose packaging signal has been modified to contain multiple tetracycline operator (tetO) sites.
  • tetO tetracycline operator
  • Packaging of the helper virus can be restored by growing the cells and virus in the presence of tetracycline, which binds to the tet-KRAB repressor causing its dissociation from the tetO/packaging signal and a reversal of packaging repression.
  • tetracycline which binds to the tet-KRAB repressor causing its dissociation from the tetO/packaging signal and a reversal of packaging repression.
  • Example 1 Construction of the E1A/E1B vector To generate an expression vector which harbors only the E1A/E1B sequences required for complementation, a 3.1 kb DNA fragment coding for Ad5 El A and EIB genes was cloned in two pieces, sequentially, into the superlinker vector, pSL301 (Invitrogen). First, an 881 bp Afl III to Xbal fragment (Ad5 base pairs 462-1343) was cloned from pBRXad5KpnICl (a subclone of pJM17) into pSL301 (Afl III/XbaI).
  • a contiguous 2194 bp Xbal to Afl II (Ad5 base pairs 1343-3537) was cloned from pBRXad5XhoIClinto the same vector.
  • the resultant 3075 bp El fragment (in pSL301) contains the TATA box and RNA cap site for El A, El A coding sequence, complete EIB promoter, and EIB coding sequence, including the stop codon for EIB p55 protein, but not including region IX.
  • This CMV-El expression plasmid (FIG. 2), was transfected using Lipofectamine (Gibco BRL) into A549 human lung carcinoma cells (ATCC CRL 185) and G418 R colonies were isolated. Single-cell clones were screened for functional E1A/E1B expression.
  • An El -deleted adenovirus containing a green florescence protein (GFP) expression cassette, Ad5 CA-GFP was used to infect the A549-E1 clones. Three days post-infection, clones were screened for production of El -complemented Ad5 CA-GFP adenovirus by visual examination for cytopathic effect (CPE).
  • CPE cytopathic effect
  • A549E1-68 displayed 100% CPE in 3 days, similar to that observed for 293 cells.
  • the clear area in the center of the plaque is evidence of CPE caused by El -complemented virus amplification.
  • This clone also showed high infectivity, in that virtually 100% of the cells fluoresced green 24 hours post-infection.
  • the high infection rate and rapid generation of CPE induced in this cell line is strong evidence that functional E1A/E1B proteins are being produced that are capable of promoting replication and amplification of the El- deleted Ad5-CA-GFP virus.
  • the A459E1 cell was deposited at the American Type Tissue Culture Collection (ATCC) under the Budapest Treaty on January 15, 1998 as ATCC Designation CRL-12458 (viability confirmed January 20, 1998).
  • FIG. 3 shows a Southern blot using an El sequence-specific DNA probe. This assay demonstrated the presence of the CMV-El transgene in A549E1-68 (Lane 4), and a subclone of A549E1-68 (El-68.3), but not in the parental A549 cell line (Lane 2). Sequences hybridizing with the El -specific probe were also observed in 293 cells as expected since they complement El-deleted adenovirus (Lane 3). The morphology of the El-transfected cells was significantly different from the parental A549 cell line.
  • A549 cells at sub-confluent density grow as distinct single cells with an elongated, fibroblast- like morphology, whereas the El cell line A549E1-68 grows as colonies of cells with a more cuboidal morphology.
  • A549E1-68 was also compared with 293 cells for production of El -deleted adenovirus (Ad5 CA-GFP) by plaque assay and found to produce an equivalent titer of complemented virus (7 x 10 9 pfu for A549E1-68 vs. 9 x 10 9 pfu for 293).
  • FIG. 4A shows a Western blot analysis using an EIA specific antibody (M73, Oncogene Science). This antibody detected two ElA-specific bands with apparent molecular weights of 46kd and 42kd in the A549E1-68 cell line (lane 3), corresponding to products expected from EIA 13S and 12S mRNAs (Ginsberg, 1984), and identical in size to those observed in 293 cells (lane 2). These El A-specific bands were not detected in parental A549 cells (lane 1).
  • FIG. 4B shows the immunoprecipitation of metabolically-radiolabeled proteins by a monoclonal antibody specific for EIB p55.
  • A549E1-68 produced an immunoreactive band of approximately 55 kd (lane 3) that was not detected in parental A549 cells. This 55 kd, ElB-specific band, as well as secondary background bands, were observed in 293 cells also (lane 2). Extra "background" bands found in both experimental and control lanes have been observed by other authors and are attributed to co-immunoprecipitation of a variety of proteins including, cyclins, p53, and Rb. It is clear that A549E1-68 not only expresses EIA and EIB, but that they are functional, since this cell line can complement for production of high titer, El -deleted, recombinant adenovirus.
  • Example 3 El-deleted adenovirus produced in A549E1 cells is RCA-free
  • Ad5 helper cell line can complement without production of RCA
  • a series of PCR RCA assays were performed following amplification in A549E1 cells of the E 1 -deleted Ad5 -CA-GFP adenovirus vector.
  • the Ad5-CA-GFP vector is illustrated in FIG. 5. It contains a transcriptional control element consisting of the CMV
  • Ad5-CA-GFP virus was serially propagated through 20 passages on A549E1-68 cells. Following serial propagation and virus amplification, Ad5-CA-GFP virus DNA was isolated by freeze-thaw lysis, and PCR was performed using primers specific for either the EIA region or the E2B region. Amplification of an 880 bp E2B product serves as a PCR positive control, while the presence of a 1086 bp El A-specific product is evidence that an El (+) replication-competent adenovirus (RCA) has been produced during amplification of the El (-) Ad5 -CA-GFP.
  • RCA replication-competent adenovirus
  • Ad5-CA- GFP virus DNA (equivalent to 1 x 10 10 virus particles), obtained from amplification in A549E1 cells, was divided into 40 PCR reactions and tested for RCA using the EIA primers (FIG. 6). For both top and bottom panels of FIG.
  • lane 1 contains 1 kb DNA markers
  • lane 2 contains wild type Ad5 virus DNA
  • lane 3 consists of PCR of Ad5-CA- GFP virus DNA (E1-) isolated from 20+ passages on A549E1-68 cells using EIA and E2B specific primers (positive control)
  • lanes 4-20 consist of PCR of Ad5-CA-GFP virus DNA (E1-) isolated from 20+ passages on A549E1-68 cells, using ElA-specific primers only. No 1086 bp El region specific PCR fragments were detected in any of the reactions indicating that no RCA was present in the virus prep.
  • a second, CPE-based RCA assay was performed by amplifying El -deleted adenovirus (Ad5-CA-GFP) on A549E1-68 cells and testing the amplified virus by passaging, on normal A549 cells (don't make El) for production of El -containing RCA. Plaque formation (CPE) on a monolayer of normal A549 cells would provide evidence for the production of wild-type (El +) virus during amplification on the El helper cell line, A549E1-68. 2 x 10 10 10 El (-) virus particles (amplified using A549E1-68) were used to infect each of five 150mm plates of normal A549 cells (1 x 10" particles total).
  • a 2nd generation El -complementing cell line was generated using the A549E1- 68.3 clonal line for transfection with Cre recombinase.
  • This cell line will both complement El -deleted adenovirus vectors and mediate the excision of sequences surrounded by loxP sites.
  • Our primary use for this cell line is to further attenuate packaging of an Ad5 helper virus, whose packaging signal is flanked by two loxP sites (FIG. 7), in order to enrich for packaging of the desired El -deficient, mini-adenovirus vector.
  • 293 cells expressing the Cre recombinase were generated for a similar purpose by Parks et al. (P.N.A.S.
  • the A549E1-Cre cell line described in this invention will not only attenuate helper virus packaging in a similar fashion, it also has the advantage that any adenovirus produced will be free of deleterious RCA.
  • a Cre expression vector was constructed as a first step towards the production of the A549E1-Cre cell line.
  • a 1440 bp SV40 promo ter-puromycin cassette (for selection in Neo R A549E1 cells) was cloned into a unique EcoRI site of the CMV-Cre vector (pBS185, Gibco/BRL) to generate pCMV-Cre-Puro (FIG. 8).
  • the pCMV-Cre- Puro vector was transfected by electroporation into A549E1-68 cells, and puromycin R (“puro R ”) clones were isolated. These puro R clones were then screened for expression of functional Cre recombinase.
  • the plasmid pBS/loxP-stop/MCLpA contains a lacZ cassette that is non-functional due to the presence of a stop codon (FIG. 9). This stop codon is surrounded by loxP sites, such that the propagation of this vector in a cell line producing Cre would excise the stop signal and activate the lacZ gene.
  • the pBS/loxP- stop/MCLpA vector was transiently transfected into each of the A549E1-Cre clones, and after 24 hours, the transfected cells were fixed and stained with X-Gal. LacZ expression of parental A549E1-68 cells (no Cre) was compared to lacZ expression in seven different puro r A549E1-Cre clones.
  • lacZ due to expression of Cre was observed as blue cells, at a frequency ranging from 1% to 50% in 20/26 puro R clones. This range of LacZ-expressing cells is most likely a reflection of the transient transfection efficiency of the different puro R clones with the pBS/loxPstop-MCLpA vector, although it could also reflect variations in Cre recombinase expression in different cell lines.
  • Western blot analysis using an anti-Cre antibody (Pharmingen) confirmed the presence of the 35 kd Cre protein in these cell lines.
  • KRAB Kruppel-associated box
  • the TetR-KRAB repressor binds to tetO sequences present in a transcriptional control region and represses transcription of genes placed as far as 3 kb downstream.
  • the present invention describes a system for tetracycline-controlled inhibition of helper virus packaging, comprising multiple tetO sequence in the helper virus packaging signal sequence, and an El helper cell line that constitutively expresses the TetR-KRAB protein.
  • the helper virus is still capable of replicating and providing all the necessary proteins, in trans, required for replication of the mini Ad vector, however, its packaging is attenuated due to binding of the TetR-KRAB protein to the tetO sites in the packaging signal.
  • the overall goal is to hinder or repress helper virus packaging, thus enriching for vector virus packaging.
  • This packaging repression is reversible, since in the presence of tetracycline, the TetR-KRAB repressor dissociates from the tetO sequences, and packaging is restored. Details of this tetO-controlled helper virus were presented in an earlier patent application (Serial No. 08/658,961, filed May 31, 1996).
  • the TetR-KRAB expressing cell line was derived using the A549E1-68 helper cell line described in Example 2.
  • A549E1-68 cells were transfected with a TetR-KRAB gene under control of the CMV promoter (see Deuschle et al., Mol. Cell. Biol. L5_ p. 1907-1914 (1995).
  • the TetR-KRAB vector also contains a hygromycin resistance gene for selection in mammalian cells.
  • a test vector see Deuschle, et al., Mol. and Cell. Biol. 15.
  • Hygromycin-resistant A549E1 -TetR-KRAB clones were transfected with pTetO-CMV-L by electroporation and each clone was split into two wells of a 6-well plate. 24 hours post-transfection, cells from one duplicate well were refed with medium containing tetracycline, and the other duplicate well in medium without tetracycline. After another 24 hours, cells were lysed and assayed for luciferase expression using a Promega Luciferase Assay Kit.
  • Two hygro R A549E1 clones (TKE-9 and TKE-12) demonstrated a 4 to 6 fold repression of luciferase reporter activity when grown in the absence of tetracycline versus cells grown in media containing Tet, indicating expression of the TetR-KRAB repressor protein in the cells (FIG. 10).
  • These A549E1 -TetR-KRAB cell lines will be used to test attenuation of the TetO-controlled Ad helper virus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à une nouvelle série de lignées cellulaires auxiliaires destinées à la complémentation, à l'amplification et à l'atténuation régulée d'adénovirus à délétion en E1. Ces lignées cellulaires présentent l'avantage de pouvoir compléter les délétions de gène dans la région E1 d'un adénovirus sans produire d'adénovirus apte à la réplication (RCA replication-competent adenovirus), ce qui les rend plus sures pour une production en masse de population d'adénovirus destinés à des essais en thérapie génique humaine. Une lignée cellulaire A549E1, qui est une réalisation préférée de cette invention, ne contient que les séquences d'ADN de la région E1 de l'adénovirus 5, suffisantes pour la complémentation de vecteurs adénoviraux à délétion en E1 sans séquence de recouvrement avec le vecteur d'adénovirus. Cette invention se rapporte en outre à des procédés de production de lignées cellulaires de complémentation A549-E1 de seconde génération qui, non seulement produisent E1, mais également des protéines nécessaires à une manipulation ultérieure des vecteurs adénoviraux. Une réalisation préférée est une lignée cellulaire A549E1 possédant des séquences d'ADN qui codent un polypeptide capable de conditionner l'atténuation du virus auxiliaire à délétion en E1, dans le but de valoriser le conditionnement de mini-adénovirus.
PCT/US1998/003473 1997-03-04 1998-02-23 Lignees cellulaires de complementation de la region e1 d'un adenovirus WO1998039411A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98908661A EP0973866A4 (fr) 1997-03-04 1998-02-23 Lignees cellulaires de complementation de la region e1 d'un adenovirus
JP10538574A JP2000509614A (ja) 1997-03-04 1998-02-23 アデノウイルスｅ１−相補性細胞系
CA002283253A CA2283253A1 (fr) 1997-03-04 1998-02-23 Lignees cellulaires de complementation de la region e1 d'un adenovirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81003997A 1997-03-04 1997-03-04
US08/810,039 1997-03-04

Publications (2)

Publication Number Publication Date
WO1998039411A1 true WO1998039411A1 (fr) 1998-09-11
WO1998039411A9 WO1998039411A9 (fr) 1999-02-25

Family

ID=25202818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003473 WO1998039411A1 (fr) 1997-03-04 1998-02-23 Lignees cellulaires de complementation de la region e1 d'un adenovirus

Country Status (4)

Country Link
EP (1) EP0973866A4 (fr)
JP (1) JP2000509614A (fr)
CA (1) CA2283253A1 (fr)
WO (1) WO1998039411A1 (fr)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048459A2 (fr) 2004-11-08 2006-05-11 Chromagenics B.V. Selection de cellules hotes exprimant une proteine a des niveaux eleves
US7132280B2 (en) 1999-04-15 2006-11-07 Crucell Holland, B.V. Recombinant protein production in a human cell
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7291484B2 (en) 2003-05-09 2007-11-06 Crucell Holland B.V. Processes for culturing E1-immortalized cells to increase product yields
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7504248B2 (en) 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
WO2011045378A1 (fr) 2009-10-15 2011-04-21 Crucell Holland B.V. Procédé de purification de particules d'adénovirus
WO2011045381A1 (fr) 2009-10-15 2011-04-21 Crucell Holland B.V. Procédé de purification d'adénovirus à partir de cultures à haute densité cellulaire
WO2011098592A1 (fr) 2010-02-15 2011-08-18 Crucell Holland B.V. Procédé de production de vecteurs adénoviraux ad26
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
JP4811765B2 (ja) * 2004-06-22 2011-11-09 学校法人東海大学 外来遺伝子の誘導発現の制御が可能な発現ベクター
US8124106B2 (en) 2004-02-23 2012-02-28 Crucell Holland B.V. Virus purification methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US8263393B2 (en) 2002-12-20 2012-09-11 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
WO2013135615A1 (fr) 2012-03-12 2013-09-19 Crucell Holland B.V. Lots d'adénovirus recombinants ayant des extrémités terminales modifiées
WO2013139911A1 (fr) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccin contre le vrs
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
US8771984B2 (en) 2004-11-08 2014-07-08 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US9228004B2 (en) 2004-11-08 2016-01-05 Chromagenics B.V. Selection of host cells expressing protein at high levels
WO2016166088A1 (fr) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Adénovirus recombiné exprimant deux transgènes avec un promoteur bidirectionnel
US9701721B2 (en) 2014-11-04 2017-07-11 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
US9790256B2 (en) 2015-08-20 2017-10-17 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
WO2017192418A1 (fr) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Combinaisons thérapeutiques de vaccins contre le hpv
WO2017220499A1 (fr) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Promoteur bidirectionnel puissant et équilibré
WO2018011196A1 (fr) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Vaccins contre le hpv
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
WO2018146205A1 (fr) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Promoteur puissant et court pour l'expression de gènes hétérologues
WO2019053109A1 (fr) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Procédé d'induction sûre de l'immunité contre le vrs
WO2019086466A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
WO2019086456A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
WO2019086450A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et ses utilisations
WO2019086461A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2020144615A1 (fr) 2019-01-10 2020-07-16 Janssen Biotech, Inc. Néo-antigènes de la prostate et leurs utilisations
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2020229579A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Traitement prophylactique d'une infection par le virus respiratoire syncytial avec un vaccin à base d'adénovirus
WO2020229577A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US10953087B2 (en) 2016-05-30 2021-03-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2021064688A1 (fr) 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
WO2021099906A1 (fr) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations
WO2021161245A1 (fr) 2020-02-14 2021-08-19 Janssen Biotech, Inc. Néoantigènes exprimés dans le myélome multiple et leurs utilisations
WO2021161244A1 (fr) 2020-02-14 2021-08-19 Janssen Biotech, Inc. Néoantigènes exprimés dans le cancer de l'ovaire et leurs utilisations
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
US11155583B2 (en) 2016-04-05 2021-10-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
WO2022009051A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Procédé de détermination de la réactivité à un traitement du cancer de la prostate
WO2022009049A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
WO2022009052A2 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
US12331077B2 (en) 2018-11-13 2025-06-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2025158316A1 (fr) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Néo-antigènes ovariens et leur utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102122117B1 (ko) * 2017-04-21 2020-06-11 (주)지뉴인텍 비복제 아데노 바이러스 생산 세포주 및 이의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034671A1 (fr) * 1994-06-10 1995-12-21 Genvec, Inc. Systemes de vecteurs adenoviraux et lignees cellulaires complementaires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US5891690A (en) * 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034671A1 (fr) * 1994-06-10 1995-12-21 Genvec, Inc. Systemes de vecteurs adenoviraux et lignees cellulaires complementaires

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANTON M., ET AL.: "SITE-SPECIFIC RECOMBINATION MEDIATED BY AN ADENOVIRUS VECTOR EXPRESSING THE CRE RECOMBINASE PROTEIN: A MOLECULAR SWITH FOR CONTROL OF GENE EXPRESSION.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 69., no. 08., 1 August 1995 (1995-08-01), US, pages 4600 - 4606., XP002912537, ISSN: 0022-538X *
DATABASE STN MEDLINE 1 January 1900 (1900-01-01), IMLER J L, ET AL: "Novel Complementation Cell Lines Derived from Human Lung Carcinoma A549 Cells Support the Growth of E1-Deleted Adenovirus Vectors", XP002912541, Database accession no. 97083340 *
DATABASE STN MEDLINE 1 January 1900 (1900-01-01), PARKS R J, ET AL: "A Helper-Dependent Adenovirus Vector System: Removal of Helper Virus by Cre-Mediated Excision of the Viral Packaging Signal", XP002912540, Database accession no. 97098434 *
DEUSCHLE U., ET AL.: "TETRACYCLINE-REVERSIBLE SILENCING OF EUKARYOTIC PROMOTERS.", MOLECULAR AND CELLULAR BIOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON., US, vol. 15., no. 04., 1 April 1995 (1995-04-01), US, pages 1907 - 1914., XP002912539, ISSN: 0270-7306 *
FALLAUX F. J., ET AL.: "CHARACTERIZATION OF 911: A NEW HELPER CELL LINE FOR THE TITRATION AND PROPAGATION OF EARLY REGION 1-DELETED ADENOVIRAL VECTORS.", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 07., 20 January 1996 (1996-01-20), US, pages 215 - 222., XP002912534, ISSN: 1043-0342 *
GAGE P. J., ET AL.: "A CELL-FREE RECOMBINATION SYSTEM FOR SITE-SPECIFIC INTEGRATION OF MULTIGENIC SHUTTLE PLASMIDS INTO THE HERPES SIMPLEX VIRUS TYPE 1 GENOME.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 66., no. 09., 1 September 1992 (1992-09-01), US, pages 5509 - 5515., XP002912536, ISSN: 0022-538X *
KANEGAE Y., ET AL.: "EFFICIENT GENE ACTIVATION IN MAMMALIAN CELLS BY USING RECOMBINANT ADENOVIRUS EXPRESSING SITE-SPECIFIC CRE RECOMBINASE.", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD., GB, vol. 23., no. 19., 1 January 1995 (1995-01-01), GB, pages 3816 - 3821., XP002912538, ISSN: 0305-1048 *
MITANI K., ET AL.: "RESCUE, PROPAGATION, AND PARTIAL PURIFICATION OF A HELPER VIRUS-DEPENDENT ADENOVIRUS VECTOR.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 92., 1 April 1995 (1995-04-01), US, pages 3854 - 3858., XP002912535, ISSN: 0027-8424, DOI: 10.1073/pnas.92.9.3854 *
See also references of EP0973866A4 *

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7132280B2 (en) 1999-04-15 2006-11-07 Crucell Holland, B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7833753B2 (en) 1999-04-15 2010-11-16 Crucell Holland B.V. Methods of producing erythropoietin isoforms comprising Lewis-X structures and high sialic acid content and compositions of the same
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7470523B2 (en) 1999-04-15 2008-12-30 Crucell Holland B.V. Recombinant protein production in a human cell
US7491532B2 (en) 1999-04-15 2009-02-17 Crucell Holland, B.V. Recombinant protein production in a human cell
US7550284B2 (en) 1999-11-26 2009-06-23 Crucell Holland B.V. Production of vaccines
US7833788B2 (en) 1999-11-26 2010-11-16 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7964198B2 (en) 1999-11-26 2011-06-21 Crucell Holland B.V. Production of vaccines
US7504248B2 (en) 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US8802417B2 (en) 2001-12-07 2014-08-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US8263393B2 (en) 2002-12-20 2012-09-11 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
US7291484B2 (en) 2003-05-09 2007-11-06 Crucell Holland B.V. Processes for culturing E1-immortalized cells to increase product yields
US7608431B2 (en) 2003-05-09 2009-10-27 Crucell Holland B.V. Fed-batch process for production of erythropoietin in human embryonic retina cells that express adenovirus E1A
US8008043B2 (en) 2003-05-09 2011-08-30 Crucell Holland B.V. Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
US8124106B2 (en) 2004-02-23 2012-02-28 Crucell Holland B.V. Virus purification methods
JP4811765B2 (ja) * 2004-06-22 2011-11-09 学校法人東海大学 外来遺伝子の誘導発現の制御が可能な発現ベクター
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
WO2006048459A2 (fr) 2004-11-08 2006-05-11 Chromagenics B.V. Selection de cellules hotes exprimant une proteine a des niveaux eleves
US9228004B2 (en) 2004-11-08 2016-01-05 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8771984B2 (en) 2004-11-08 2014-07-08 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP2402450A1 (fr) 2004-12-30 2012-01-04 Crucell Holland B.V. Procédés pour obtenir des protéines recombinantes dotées d'une structure LacdiNac diminuée
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
US8470585B2 (en) 2009-10-15 2013-06-25 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
WO2011045378A1 (fr) 2009-10-15 2011-04-21 Crucell Holland B.V. Procédé de purification de particules d'adénovirus
US8460920B2 (en) 2009-10-15 2013-06-11 Crucell Holland B.V. Method for the purification of adenovirus particles
WO2011045381A1 (fr) 2009-10-15 2011-04-21 Crucell Holland B.V. Procédé de purification d'adénovirus à partir de cultures à haute densité cellulaire
WO2011098592A1 (fr) 2010-02-15 2011-08-18 Crucell Holland B.V. Procédé de production de vecteurs adénoviraux ad26
WO2013135615A1 (fr) 2012-03-12 2013-09-19 Crucell Holland B.V. Lots d'adénovirus recombinants ayant des extrémités terminales modifiées
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013139916A1 (fr) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccin contre le vrs
WO2013139911A1 (fr) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccin contre le vrs
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EP3421046A1 (fr) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Vaccins hpv16 thérapeutiques
US11040096B2 (en) 2014-11-04 2021-06-22 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
US9701721B2 (en) 2014-11-04 2017-07-11 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
US10071151B2 (en) 2014-11-04 2018-09-11 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
US10555996B2 (en) 2014-11-04 2020-02-11 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016166088A1 (fr) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Adénovirus recombiné exprimant deux transgènes avec un promoteur bidirectionnel
US11034731B2 (en) 2015-07-07 2021-06-15 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US11998597B2 (en) 2015-07-07 2024-06-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US11229694B2 (en) 2015-07-07 2022-01-25 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
US9790256B2 (en) 2015-08-20 2017-10-17 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
US10287323B2 (en) 2015-08-20 2019-05-14 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
US10844096B2 (en) 2015-08-20 2020-11-24 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
US12234264B2 (en) 2016-04-05 2025-02-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
US11338031B2 (en) 2016-04-05 2022-05-24 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US11801297B2 (en) 2016-04-05 2023-10-31 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US11155583B2 (en) 2016-04-05 2021-10-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
WO2017192418A1 (fr) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Combinaisons thérapeutiques de vaccins contre le hpv
US11759514B2 (en) 2016-05-30 2023-09-19 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
US10953087B2 (en) 2016-05-30 2021-03-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2017220499A1 (fr) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Promoteur bidirectionnel puissant et équilibré
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
WO2018011196A1 (fr) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Vaccins contre le hpv
WO2018146205A1 (fr) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Promoteur puissant et court pour l'expression de gènes hétérologues
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019053109A1 (fr) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Procédé d'induction sûre de l'immunité contre le vrs
WO2019086456A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
WO2019086450A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et ses utilisations
US11142551B2 (en) 2017-10-31 2021-10-12 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
WO2019086466A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
US11872281B2 (en) 2017-10-31 2024-01-16 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
US11236361B2 (en) 2017-10-31 2022-02-01 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
WO2019086461A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
US12331077B2 (en) 2018-11-13 2025-06-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2020144615A1 (fr) 2019-01-10 2020-07-16 Janssen Biotech, Inc. Néo-antigènes de la prostate et leurs utilisations
US11793843B2 (en) 2019-01-10 2023-10-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2020229577A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
WO2020229579A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Traitement prophylactique d'une infection par le virus respiratoire syncytial avec un vaccin à base d'adénovirus
WO2021064688A1 (fr) 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
WO2021099906A1 (fr) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2021161244A1 (fr) 2020-02-14 2021-08-19 Janssen Biotech, Inc. Néoantigènes exprimés dans le cancer de l'ovaire et leurs utilisations
WO2021161245A1 (fr) 2020-02-14 2021-08-19 Janssen Biotech, Inc. Néoantigènes exprimés dans le myélome multiple et leurs utilisations
US11945881B2 (en) 2020-02-14 2024-04-02 Janssen Biotech, Inc. Neoantigens expressed in ovarian cancer and their uses
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
WO2022009052A2 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
WO2022009049A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
WO2022009051A1 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Procédé de détermination de la réactivité à un traitement du cancer de la prostate
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2025158316A1 (fr) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Néo-antigènes ovariens et leur utilisation

Also Published As

Publication number Publication date
EP0973866A1 (fr) 2000-01-26
EP0973866A4 (fr) 2000-04-19
CA2283253A1 (fr) 1998-09-11
JP2000509614A (ja) 2000-08-02

Similar Documents

Publication Publication Date Title
WO1998039411A1 (fr) Lignees cellulaires de complementation de la region e1 d'un adenovirus
WO1998039411A9 (fr) Lignees cellulaires de complementation de la region e1 d'un adenovirus
Zhang et al. Role for the adenovirus IVa2 protein in packaging of viral DNA
US6228646B1 (en) Helper-free, totally defective adenovirus for gene therapy
Massie et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette
JP3492700B2 (ja) 遺伝子治療のためのアデノウィルスベクター
Holterman et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5
US6365394B1 (en) Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US6140087A (en) Adenovirus vectors for gene therapy
EP0705344A1 (fr) Vecteurs a base d'adenovirus destines a la therapie genique
IL160406A (en) A cell containing nucleic acid encoding E1A and E1B gene products
US20020037280A1 (en) Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof
Catalucci et al. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent ΔE1-E2-E3-E4 Ad5 vectors
AU752284B2 (en) Methods for pseudoadenoviral vector production
Wang et al. Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression
US20010046965A1 (en) Adenovirus E1-complementing cell lines
Bernt et al. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication
Gall et al. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes
Murakami et al. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations
JP2004517610A (ja) 自己再編成性ｄｎａベクター
Fang et al. Diminishing adenovirus gene expression and viral replication by promoter replacement
McVoy et al. Tetracycline-mediated regulation of gene expression within the human cytomegalovirus genome
EP1127149B1 (fr) Cellules pour produire des vecteurs adenoviraux dependant de virus auxiliaires, et procede de preparation et d'utilisation de ces cellules
Howe et al. Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors
Kasai et al. DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

ENP Entry into the national phase

Ref document number: 2283253

Country of ref document: CA

Ref country code: CA

Ref document number: 2283253

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998908661

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 538574

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998908661

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998908661

Country of ref document: EP